



UNC
HEALTH CARE

MEMORANDUM #123

TO: UNC Hospitals Attending Physicians, Housestaff, Nursing Coordinators,
Department Heads and Supervisors

FROM: *CH* Catherine A. Hammett-Stabler, Ph.D., DABCC, FACB
Director of Core Laboratories, McLendon Clinical Laboratories

NKS Nichole Korpi-Steiner, Ph.D.
Associate Director of Core Laboratories, McLendon Clinical Laboratories

HW Herbert C. Whinna, M.D., Ph.D.
Medical Director, McLendon Clinical Laboratories

CC Christian Cristobal, MT(ASCP)
Assistant Administrative Director, Core Laboratory

SUBJECT: AFP tumor marker testing

DATE: April 27, 2015

The Core Laboratory announces the change of testing platforms for Alpha-Fetoprotein (AFP) tumor marker testing effective May 11, 2015. The AFP tumor marker testing is currently performed in the Core Laboratory using the Access 2 analyzer (Beckman Coulter) and the testing will be moved to the Vitros 5600 analyzer (Ortho Clinical Diagnostics).

Testing Availability: Testing will be performed daily.

Reference Range and Interpretation: < 7.51 ng/mL

Testing Notes: AFP results obtained using the Vitros 5600 demonstrate a small negative bias compared with the Access 2 method (Linear Regression analysis: [Vitros 5600 AFP] = 0.93 * [Access 2 AFP] + 1.66; R²=0.996). Please contact the Core Laboratory should it be necessary to reestablish patient's AFP baseline concentration.

For questions or more information regarding this change in testing, please contact Dr. Korpi-Steiner or Christian Cristobal at 974-2361.